Community/Retail

The actions will support the development of psychedelic-based therapies for PTSD, depressive disorders, and substance use disorders.

The reclassification of medical marijuana to Schedule III marks a major policy shift that expands research and introduces new potential health care challenges.

This week's episode highlights a new executive order signed by President Trump, new expanded FDA approvals, and a conference roundup.

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.

A cognitive neurologist outlines the current Alzheimer disease treatment landscape.

Pharmacists must remain in a constant state of readiness by implementing structured shortage management plans and guiding patients through access challenges as supply disruptions persist.

Extended data from ACHIEVE-4 reinforce the durability of oral GLP-1 receptor agonist therapy, with implications for long-term diabetes management and pharmacist-led care.

New Yale University research offers reassurance for pregnant patients and their clinicians, although evidence of lasting structural damage remains a concern.

AI is delivering immediate clinical value in neurology—from ambient scribes and clinical decision support to trial recruitment and medical education.

A Harvard population health researcher presents findings linking adolescent food insecurity to a cluster of brain health risk factors.

Performing medication reconciliations and assessing for drug interactions are examples of strategies to prevent medication errors.

A large multicohort analysis highlights obesity as a modifiable risk factor for severe infectious outcomes, reinforcing the pharmacist’s role in prevention, vaccination, and chronic disease management.

Global trade disruptions and reliance on overseas manufacturing could contribute to future drug shortages, highlighting the need for proactive planning and supply chain resilience across pharmacy settings.

National certification, advanced specialization, and informatics enhance career longevity and patient safety

Cannabidiol may have broader applicability across genetic developmental and epileptic encephalopathies (DEEs).

FDA approval expands teplizumab-mzwv to patients 1 year and older, helping delay type 1 diabetes onset for children with stage 2 diabetes.

Bocunebart, a novel anti-PACAP antibody, targets a distinct neurological pathway from existing CGRP therapies.

The approval of doravirine and islatravir marks a new 2-drug, once-daily oral option for HIV-1 management, with implications for treatment simplification, adherence, and pharmacist-led antiretroviral care.

PTCB credentialing elevates pharmacy technicians’ safety and career commitment, boosts patient trust, and enables efficient delegation—helping reduce medication errors in modern pharmacies.

Geopolitical conflict could affect drug manufacturing and global trade routes, with potential downstream impacts on medication costs and availability.

Cemdisiran’s RNA-targeting mechanism is a compelling new option in the generalized myasthenia gravis treatment landscape.

A new study supports the use of PREVENT equations in routine clinical practice, reinforcing their role in cardiovascular risk assessment and pharmacist-led prevention strategies.

Learn how pharmacists vet financial planners: CFP credentials, true fiduciary duty, fee transparency, and six questions to avoid costly mistakes.

A federal directive to expedite FDA review and expand research pathways for psychedelic therapies signals a potential shift in mental health treatment.

Lowering costs won’t improve health outcomes if the pharmacies dispensing those medications lack the authority, staffing, and infrastructure to function as clinical settings.

Emerging data find buprenorphine in pregnancy matches methadone for autism and ADHD risk, supporting safer opioid MOUD access in pharmacy care.